MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SCHULZ, R.
Right arrow Articles by HERZ, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCHULZ, R.
Right arrow Articles by HERZ, A.

Molecular Pharmacology, Vol 18, 395-401, Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics

Lack of Cross-Tolerance on Multiple Opiate Receptors in the Mouse Vas Deferens

RÜDIGER SCHULZ 1, MICHAEL WÜSTER 1, HEINZ KRENSS 1, and ALBERT HERZ 1

1 Department of Neuropharmacology, Max-Planck-Institut für Psychiatrie, Kraepelinstrasse 2, D-8000 München 40, Federal Republic of Germany

The development of opiate tolerance has been studied in the mouse vas deferens, which contains µ- and dgr-opiate receptors. Long-term infusion of opioids acting selectively on either µ- or dgr-receptors was accomplished by means of osmotic minipumps. In vitro tests of vasa deferentia from chronically [D-Ala2,D-Leu5]enkephalin (DADL)-treated mice revealed an 800-fold degree of tolerance for dgr-receptors, while µ-receptors were left unaffected. Accordingly, cross-tolerance to dgr-receptor agonists, e.g., leucine-enkephalin, was observed but not to µ-receptor agonists, e.g., normorphine. On the other hand, infusion of the potent opioid sufentanyl, which almost selectively acts at µ-receptors, brings about a high degree of tolerance for µ-receptor agonists, but causes no change in sensitivity to dgr-receptor agonists. A number of opioids, including beta-endorphin, exhibit some degree of cross-tolerance in dgr-receptor-tolerant as well as in µ-receptor-tolerant preparations. Essentially identical results were obtained in vasa deferentia made acutely tolerant in vitro using the dgr-receptor agonist DADL. Challenge of highly tolerant vasa deferentia with the narcotic antagonist naloxone failed to demonstrate any withdrawal sign. The failure to demonstrate dependence in highly tolerant vasa deferentia may be due to adaptational processes upon chronic opioid exposure at the opiate receptor binding site level. It is concluded that opiate receptor differentiation can be reliably achieved by means of their selective tolerance development.

Note:
ACKNOWLEDGMENTS The expert technical assistance of Ms. A. Wilhelm is greatly appreciated. We would like to thank Dr. J. Dum for stylistic corrections of the manuscript. We are grateful to Dr. Heykants for donating sufentanyl and to Dr. Ling for a gift of beta-lipotropin61-79.

Submitted on March 6, 1980
Accepted on May 20, 1980




This article has been cited by other articles:


Home page
ScienceHome page
K. Rice, A. Jacobson, T. Burke Jr, B. Bajwa, R. Streaty, and W. Klee
Irreversible ligands with high selectivity toward delta and mu opiate receptors
Science, April 15, 1983; 220(4594): 314 - 316.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics